Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
A study published in the The demand for GLP-1 agonists, including Novo Nordisk A/S's (NYSE:NVO) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
包括Novo Nordisk A/S（紐交所：NVO）的奧塞康和Wegovy（塞馬魯替德）在內，GLP-1激動劑的需求持續增長，這是一類用於管理糖尿病和肥胖的藥物。
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for cardiovascular indication for Wegovy and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the promise of these treatments.
儘管最初是爲2型糖尿病而開發的，但GLP-1激動劑因其在體重管理方面的有效性而受到關注。FDA的批准擴大了Wegovy的心血管適應症的使用範圍，併爲慢性腎病和非酒精性脂肪肝炎（NASH）的潛在未來應用進一步強調了這些治療的潛力。
The Forbes report adds that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
福布斯報告補充稱，實際世界的證據顯示，GLP-1使用導致的體重減輕可能與臨床試驗中觀察到的結果不同。
A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.
《美國醫學會雜誌》（JAMA）發表的一項研究揭示，病人平均在藥物使用一年後只有3.7%的體重減輕，低於控制試驗中報告的結果。
Also Read: Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday.
此外閱讀：Novo Nordisk首席執行官將因奧塞康和Wegovy的高價格接受參議院審查，聽證會定於週二舉行。
While patients have high expectations for substantial weight loss, the findings suggest that most individuals did not experience the same degree of benefit as seen in clinical settings.
儘管病人對於大幅減重抱有很高期望，但研究結果表明，大多數患者未能體驗到臨床環境中觀察到的同等益處。
However, those who persisted with GLP-1 therapy saw results comparable to those in clinical trials.
然而，那些堅持GLP-1療法的患者看到的結果與控制試驗中的結果相當。
In another study published in 2023, researchers observed a modest average weight loss of 2.2% over 72 weeks among type 2 diabetes patients on GLP-1s.
在2023年發表的另一項研究中，研究人員觀察到2型糖尿病患者在GLP-1使用的72周內有2.2%的平均體重減輕。
Additionally, a pre-print analysis this year found that the real-world effectiveness of GLP-1s was less pronounced than in randomized controlled trials.
此外，今年一項預印分析發現，GLP-1藥物在現實世界中的有效性不如隨機對照試驗中明顯。
This difference underscores the challenge of replicating clinical trial success in everyday medical settings, where factors like medication adherence and real-life conditions are involved.
這種差異凸顯了在日常醫療環境中複製臨床試驗成功的挑戰，涉及藥物依從性和真實生活條件等因素。
Persistence with GLP-1 medications is a significant issue. Forbes reported that only 15% of patients who started GLP-1 drugs for weight loss remained on them after two years, citing Prime Therapeutics, a pharmacy benefit manager.
GLP-1藥物的依從性是一個重要問題。據福布斯報道，只有15%的開始使用GLP-1減重藥物的患者在兩年後仍在使用，援引藥房福利管理公司Prime Therapeutics的數據。
Discontinuation rates were high, with just 29% continuing treatment after one year and a mere 15% after two years.
停藥率很高，僅有29%的患者在一年後繼續治療，兩年後僅有15%。
Other studies, including findings from Blue Cross Blue Shield, show that many patients stop GLP-1 therapy early, often within the first month, before achieving meaningful weight loss.
其他研究，包括藍十字藍盾公司的研究結果顯示，許多患者在未實現明顯減重之前就早早放棄了GLP-1療法，在第一個月內經常停止使用。
- Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected.
- 《醫療報告》評審者公佈第二輪醫保藥品價格談判細則，預計將實現150億美元的節省。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
